Table III.
Service | No progression (n = 734) | Progression (n = 268) | Cp–CNP | Cp/CNP | p-Value* |
---|---|---|---|---|---|
Overall cost | 859.98 | 3527.4 | 2667.4 | 4.10 | <0.001 |
Outpatient visits | 36.68 | 99.92 | 63.24 | 2.72 | <0.001 |
Acute care† | 2.46 | 24.14 | 21.68 | 9.81 | <0.001 |
Chemotherapy | 655.75 | 2495.01 | 1839.26 | 3.8 | <0.001 |
R-mono | 487.07 | 849.50 | 362.43 | 1.74 | <0.001 |
R-chemo | 166.07 | 1610.86 | 1444.79 | 9.69 | <0.001 |
Chemo | 2.61 | 34.65 | 32.04 | 13.27 | <0.001 |
Other medication | 101.86 | 700.28 | 598.42 | 6.87 | <0.001 |
Laboratories | 11.35 | 28.53 | 17.18 | 2.51 | <0.001 |
Minor procedures | 2.79 | 8.79 | 6.00 | 3.15 | <0.001 |
Other | 0.59 | 3.02 | 2.43 | 5.11 | <0.001 |
XRT | 15.07 | 71.27 | 38.93 | 4.72 | <0.001 |
RAD non-XRT | 32.59 | 95.41 | 62.82 | 2.92 | <0.001 |
Cp, cost of progression; CNp, cost of not progressing; R-mono, rituximab monotherapy; R-chemo, rituximab-chemotherapy; Chemo, chemotherapy only; XRT, external radiation treatment; RAD non-XRT, radiation other than XRT.
Mann-Whitney U-test.
lnpatient and ER visits.